There is a new LAI called Perseris, which is a subcutaneous formulation of long-acting risperidone. It is the first LAI to be administered subcutaneously rather than intramuscularly. A subcutaneous injection is given with a short needle and injected under the skin, into the tissue layer between the skin and the muscle.
It is FDA-approved to treat schizophrenia. You should discuss this option with your psychiatrist or PMHNP in order to determine whether this LAI is right for you. See this SMI Adviser tip for more information on Perseris.